Europe Intravenous Immunoglobulin Market Size & Outlook
Europe intravenous immunoglobulin market, 2018-2030 (US$M)
Related Markets
Europe intravenous immunoglobulin market highlights
- The Europe intravenous immunoglobulin market generated a revenue of USD 3,424.9 million in 2024.
- The market is expected to grow at a CAGR of 6.8% from 2025 to 2030.
- In terms of segment, immunodeficiency diseases was the largest revenue generating application in 2024.
- Kawasaki Disease is the most lucrative application segment registering the fastest growth during the forecast period.
- Country-wise, UK is expected to register the highest CAGR from 2025 to 2030.
Europe data book summary
| Market revenue in 2024 | USD 3,424.9 million |
| Market revenue in 2030 | USD 5,106.7 million |
| Growth rate | 6.8% (CAGR from 2025 to 2030) |
| Largest segment | Immunodeficiency diseases |
| Fastest growing segment | Kawasaki Disease |
| Historical data covered | 2018 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Immunodeficiency diseases, CIDP, Hypogammaglobulinemia, Congenital AIDS, Chronic Lymphocytic Leukemia, Myasthenia Gravis, Multifocal Motor Neuropathy, ITP, Kawasaki Disease, Guillain-Barre Syndrome |
| Key market players worldwide | Biotest AG ADR, Baxter International Inc, Grifols SA Ordinary Shares - Class A, CSL Ltd, Octapharma AG, LFB (Laboratoire Français du Fractionnement et des Biotechnologies), Taibang Biological Group, Kedrion Biopharma |
Other key industry trends
- In terms of revenue, Europe region accounted for 24.7% of the global intravenous immunoglobulin market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 5,201.7 million by 2030.
Immunodeficiency diseases was the largest segment with a revenue share of 20.91% in 2024. Horizon Databook has segmented the Europe intravenous immunoglobulin market based on immunodeficiency diseases, cidp, hypogammaglobulinemia, congenital aids, chronic lymphocytic leukemia, myasthenia gravis, multifocal motor neuropathy, itp, kawasaki disease, guillain-barre syndrome covering the revenue growth of each sub-segment from 2018 to 2030.
The European IVIG market is also experiencing rapid growth, driven by increasing awareness of immunodeficiency diseases and the availability of effective IVIG therapies for conditions like CIDP, Guillain-Barre Syndrome, and Kawasaki disease. Countries like the UK, Germany, and France are witnessing a steady rise in the demand for IVIG products, particularly through hospital pharmacies and specialty pharmacies. The region’s growth is further supported by initiatives from key players like Grifols SA, CSL, and LFB, who are competing to expand their presence in the European market.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Intravenous Immunoglobulin Market Scope
Intravenous Immunoglobulin Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Europe intravenous immunoglobulin market size, by country, 2018-2030 (US$M)
Europe Intravenous Immunoglobulin Market Outlook Share, 2024 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
